Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN) with bullish sentiments.

Soleno Therapeutics Inc (NASDAQ: SLNO)

Maxim Group analyst Gabrielle Zhou assigned a Buy rating to Soleno Therapeutics Inc (NASDAQ: SLNO) today and set a price target of $5. The company’s shares opened today at $0.62.

Zhou noted:

“Soleno today announced the issuance of a new patent (9,757,384) from the U.S. Patent and Trademark Office for the use of pharmaceutical formulations of diazoxide and diazaxide choline (Diazoxide Choline Controlled Release Tablet; DCCR) to reduce aggressive behaviors in patients with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).”

According to TipRanks.com, Zhou is a 4-star analyst with an average return of 11.5% and a 53.5% success rate. Zhou covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Cellular Biomedicine Group.

Soleno Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.

Alexion Pharmaceuticals (NASDAQ: ALXN)

In a report released yesterday, Ian Somaiya from BMO Capital reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), with a price target of $173. The company’s shares opened today at $144.11, close to its 52-week high of $149.34.

According to TipRanks.com, Somaiya is a 5-star analyst with an average return of 20.0% and a 62.9% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Aeglea Biotherapeutics Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Alexion Pharmaceuticals is Strong Buy and the average price target is $162.18, representing a 12.5% upside.

In a report issued on September 5, J.P. Morgan also upgraded the stock to Buy with a $175 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.